195 related articles for article (PubMed ID: 28903520)
21. Antiretroviral therapy responses among children attending a large public clinic in Soweto, South Africa.
Meyers TM; Yotebieng M; Kuhn L; Moultrie H
Pediatr Infect Dis J; 2011 Nov; 30(11):974-9. PubMed ID: 21734620
[TBL] [Abstract][Full Text] [Related]
22. Comparative Impact of Suppressive Antiretroviral Regimens on the CD4/CD8 T-Cell Ratio: A Cohort Study.
Masiá M; Padilla S; Barber X; Sanchis M; Terol G; Lidón F; Gutiérrez F
Medicine (Baltimore); 2016 Mar; 95(11):e3108. PubMed ID: 26986155
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.
Penazzato M; Prendergast A; Tierney J; Cotton M; Gibb D
Cochrane Database Syst Rev; 2012 Jul; (7):CD004772. PubMed ID: 22786492
[TBL] [Abstract][Full Text] [Related]
24. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
[TBL] [Abstract][Full Text] [Related]
25. HIV viral suppression and longevity among a cohort of children initiating antiretroviral therapy in Eastern Cape, South Africa.
Teasdale CA; Sogaula N; Yuengling KA; Wang C; Mutiti A; Arpadi S; Nxele M; Pepeta L; Mogashoa M; Rivadeneira ED; Abrams EJ
J Int AIDS Soc; 2018 Aug; 21(8):e25168. PubMed ID: 30094952
[TBL] [Abstract][Full Text] [Related]
26. Time to Switch to Second-line Antiretroviral Therapy in Children With Human Immunodeficiency Virus in Europe and Thailand.
European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group in EuroCoord
Clin Infect Dis; 2018 Feb; 66(4):594-603. PubMed ID: 29029056
[TBL] [Abstract][Full Text] [Related]
27. Drug resistance outcomes of long-term ART with tenofovir disoproxil fumarate in the absence of virological monitoring.
Villa G; Phillips RO; Smith C; Stockdale AJ; Ruggiero A; Beloukas A; Appiah LT; Chadwick D; Sarfo FS; Geretti AM
J Antimicrob Chemother; 2018 Nov; 73(11):3148-3157. PubMed ID: 30032305
[TBL] [Abstract][Full Text] [Related]
28. Growth Recovery Among HIV-infected Children Randomized to Lopinavir/Ritonavir or NNRTI-based Antiretroviral Therapy.
Achan J; Kakuru A; Ikilezi G; Mwangwa F; Plenty A; Charlebois E; Young S; Havlir D; Kamya M; Ruel T
Pediatr Infect Dis J; 2016 Dec; 35(12):1329-1332. PubMed ID: 27580060
[TBL] [Abstract][Full Text] [Related]
29. Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.
Paton NI; Kityo C; Thompson J; Nankya I; Bagenda L; Hoppe A; Hakim J; Kambugu A; van Oosterhout JJ; Kiconco M; Bertagnolio S; Easterbrook PJ; Mugyenyi P; Walker AS;
Lancet HIV; 2017 Aug; 4(8):e341-e348. PubMed ID: 28495562
[TBL] [Abstract][Full Text] [Related]
30. Switching to Efavirenz Versus Remaining on Ritonavir-boosted Lopinavir in Human Immunodeficiency Virus-infected Children Exposed to Nevirapine: Long-term Outcomes of a Randomized Trial.
Murnane PM; Strehlau R; Shiau S; Patel F; Mbete N; Hunt G; Abrams EJ; Coovadia A; Kuhn L
Clin Infect Dis; 2017 Aug; 65(3):477-485. PubMed ID: 28419200
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of efavirenz compared with ritonavir-boosted protease-inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/ml.
Imaz A; Llibre JM; Navarro J; Curto J; Clotet B; Crespo M; Ferrer E; Saumoy M; Tiraboschi JM; Murillo O; Podzamczer D
Antivir Ther; 2014; 19(6):569-77. PubMed ID: 24458091
[TBL] [Abstract][Full Text] [Related]
32. Discontinuation of Efavirenz in Paediatric Patients: Why do Children Switch?
Wynberg E; Williams E; Tudor-Williams G; Lyall H; Foster C
Clin Drug Investig; 2018 Mar; 38(3):231-238. PubMed ID: 29181714
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors.
Robbins BL; Capparelli EV; Chadwick EG; Yogev R; Serchuck L; Worrell C; Smith ME; Alvero C; Fenton T; Heckman B; Pelton SI; Aldrovandi G; Borkowsky W; Rodman J; Havens PL;
Antimicrob Agents Chemother; 2008 Sep; 52(9):3276-83. PubMed ID: 18625762
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.
Gay CL; Mayo AJ; Mfalila CK; Chu H; Barry AC; Kuruc JD; McGee KS; Kerkau M; Sebastian J; Fiscus SA; Margolis DM; Hicks CB; Ferrari G; Eron JJ;
AIDS; 2011 Apr; 25(7):941-9. PubMed ID: 21487250
[TBL] [Abstract][Full Text] [Related]
35. [Lopinavir/ritonavir in new initial antiretroviral treatment strategies].
Rolón MJ; Figueroa MI; Sued O; Cahn P
Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():7-11. PubMed ID: 25542869
[TBL] [Abstract][Full Text] [Related]
36. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.
Torriani FJ; Komarow L; Parker RA; Cotter BR; Currier JS; Dubé MP; Fichtenbaum CJ; Gerschenson M; Mitchell CK; Murphy RL; Squires K; Stein JH;
J Am Coll Cardiol; 2008 Aug; 52(7):569-76. PubMed ID: 18687253
[TBL] [Abstract][Full Text] [Related]
37. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial.
Cahn P; Andrade-Villanueva J; Arribas JR; Gatell JM; Lama JR; Norton M; Patterson P; Sierra Madero J; Sued O; Figueroa MI; Rolon MJ;
Lancet Infect Dis; 2014 Jul; 14(7):572-80. PubMed ID: 24783988
[TBL] [Abstract][Full Text] [Related]
38. Risk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir/ritonavir- or efavirenz-based antiretroviral therapy.
Koss CA; Natureeba P; Plenty A; Luwedde F; Mwesigwa J; Ades V; Charlebois ED; Clark TD; Achan J; Ruel T; Nzarubara B; Kamya MR; Havlir DV; Cohan D
J Acquir Immune Defic Syndr; 2014 Oct; 67(2):128-35. PubMed ID: 25072616
[TBL] [Abstract][Full Text] [Related]
39. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
40. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
Neukam K; Mira JA; Ruiz-Morales J; Rivero A; Collado A; Torres-Cornejo A; Merino D; de Los Santos-Gil I; Macías J; González-Serrano M; Camacho A; Parra-García G; Pineda JA;
J Antimicrob Chemother; 2011 Nov; 66(11):2605-14. PubMed ID: 21903660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
